Is dexlansoprazole approved for use during pregnancy?

Dexlansoprazole Use in Pregnancy

Dexlansoprazole is not formally "approved" for pregnancy, but available evidence suggests it can be used when clinically indicated, as observational data on its parent compound lansoprazole shows no increased risk of major congenital malformations. 1

FDA Labeling and Risk Assessment

The FDA label for dexlansoprazole explicitly states there are no studies in pregnant women to inform drug-associated risk. However, the label provides reassuring data based on lansoprazole (dexlansoprazole is the R-enantiomer of lansoprazole):

• Published observational studies of lansoprazole use during pregnancy did not demonstrate an association with adverse pregnancy-related outcomes 1
• Multiple studies support safety:
  • European Network study: 62 pregnant women on lansoprazole showed no difference in major malformations vs. controls (RR=1.04,95% CI 0.25-4.21) 1
  • Danish cohort: 794 first-trimester exposures showed no significant increase in major birth defects 1
  • Meta-analysis: 1,530 PPI-exposed pregnancies showed no significant increases in congenital malformations (OR=1.12,95% CI 0.86-1.45) or spontaneous abortion (OR=1.29,95% CI 0.84-1.97) 1

Clinical Context and Recommendations

For pregnant women requiring acid suppression therapy, the decision should weigh maternal benefit against theoretical fetal risk, with the understanding that untreated severe gastroesophageal reflux can compromise maternal nutrition and quality of life.

Treatment Algorithm:

1. First-line: Non-systemic agents (antacids, sucralfate) for mild-moderate symptoms 2

2. Second-line: H2-receptor antagonists (avoiding nizatidine) or prokinetic agents for moderate symptoms 2

3. Third-line: PPIs including dexlansoprazole for severe, intractable symptoms or when other therapies fail 2

Important Caveats

• Recent pharmacovigilance data from FAERS database (2004-2025) identified potential signals for lansoprazole including pregnancy on contraception and fetal growth restriction, though these are hypothesis-generating and require confirmation 3

• Animal studies at doses up to 9 times the maximum human dose showed no fetal effects in rabbits; rat studies at 1.8 times human dose showed minor skeletal effects associated with reduced body weight 1

• The background risk in the US general population is 2-4% for major birth defects and 15-20% for miscarriage 1

Practical Guidance

Use dexlansoprazole during pregnancy when:

• Severe gastroesophageal reflux symptoms persist despite lifestyle modifications and first-line therapies
• Maternal nutritional status or quality of life is significantly compromised
• The clinical benefit clearly justifies use

Counsel patients that:

• No definitive human safety data exist specifically for dexlansoprazole
• Observational data on lansoprazole (the parent compound) is reassuring
• The drug is not contraindicated, but should be reserved for cases where benefit outweighs theoretical risk
• Inadvertent exposure would not be considered grounds for pregnancy termination 4